Compare Stocks

→ [Shocking] Elon Musk’s Plan To End Banks (From Crypto 101 Media) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APTX Aptinyx	$0.10 +3.1%	$0.08	$0.01 ▼ $0.72	N/A	1.27	1.32 million shs	231,100 shs
ETON Eton Pharmaceuticals	$3.25 +1.9%	$3.96	$2.42 ▼ $5.81	$83.49M	1.17	68,466 shs	39,976 shs
HBPCF Helix BioPharma	$0.14	$0.14	$0.14 ▼ $0.15	$31.59M	-0.1	900 shs	N/A
SBBP Strongbridge Biopharma	$2.00	$2.09	$1.85 ▼ $4.26	$135.66M	1.58	866,464 shs	684,684 shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APTX Aptinyx	0.00%	0.00%	0.00%	0.00%	-21.57%
ETON Eton Pharmaceuticals	+1.88%	+0.93%	-17.93%	-27.29%	-8.96%
HBPCF Helix BioPharma	0.00%	0.00%	-6.96%	-5.03%	-5.81%
SBBP Strongbridge Biopharma	0.00%	0.00%	0.00%	0.00%	0.00%

[Shocking] Elon Musk’s Plan To End Banks (Ad)

Leaked Elon Musk call reveals shocking plan to replace banks. As Musk's plan rolls out, industry experts predict it could spark a wave of mass crypto adoption. Triggering a new crypto bull run. While helping drive a booming crypto asset class up from $2.5-billion to $16-trillion (a 6,400x increase) by 2030.

Click here now to get your copy.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
APTX Aptinyx	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ETON Eton Pharmaceuticals	2.3873 of 5 stars	3.5	5.0	0.0	0.0	2.7	0.8	0.0
HBPCF Helix BioPharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SBBP Strongbridge Biopharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APTX Aptinyx	N/A	N/A	N/A	N/A
ETON Eton Pharmaceuticals	3.00	Buy	$10.00	207.69% Upside
HBPCF Helix BioPharma	N/A	N/A	N/A	N/A
SBBP Strongbridge Biopharma	N/A	N/A	N/A	N/A

Current Analyst Ratings

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APTX Aptinyx	$1M	N/A	N/A	N/A	$0.57 per share	N/A
ETON Eton Pharmaceuticals	$31.64M	2.64	N/A	N/A	$0.60 per share	5.42
HBPCF Helix BioPharma	N/A	N/A	N/A	N/A	N/A	N/A
SBBP Strongbridge Biopharma	$30.73M	4.41	N/A	N/A	$0.98 per share	2.04

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APTX Aptinyx	-$64.85M	-$0.98	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ETON Eton Pharmaceuticals	-$940K	-$0.03	N/A	∞	N/A	-2.96%	-6.21%	-3.17%	5/9/2024 (Estimated)
HBPCF Helix BioPharma	-$4.69M	-$0.04	N/A	∞	N/A	N/A	-817.64%	-308.71%	6/12/2024 (Estimated)
SBBP Strongbridge Biopharma	-$45.08M	-$0.78	N/A	N/A	N/A	-115.67%	-66.82%	-36.21%	N/A

Latest SBBP, ETON, APTX, and HBPCF Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/14/2024	Q4 2023	ETON Eton Pharmaceuticals	-$0.04	-$0.09	-$0.05	-$0.09	$7.70 million	$7.31 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
APTX Aptinyx	N/A	N/A	N/A	N/A	N/A
ETON Eton Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
HBPCF Helix BioPharma	N/A	N/A	N/A	N/A	N/A
SBBP Strongbridge Biopharma	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APTX Aptinyx	N/A	N/A	N/A
ETON Eton Pharmaceuticals	N/A	1.65	1.60
HBPCF Helix BioPharma	N/A	1.46	1.46
SBBP Strongbridge Biopharma	0.38	3.00	2.95

Ownership

Institutional Ownership

Company	Institutional Ownership
APTX Aptinyx	N/A
ETON Eton Pharmaceuticals	27.86%
HBPCF Helix BioPharma	N/A
SBBP Strongbridge Biopharma	52.03%

Insider Ownership

Company	Insider Ownership
APTX Aptinyx	10.97%
ETON Eton Pharmaceuticals	13.16%
HBPCF Helix BioPharma	7.60%
SBBP Strongbridge Biopharma	5.10%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
APTX Aptinyx	12	N/A	N/A	Not Optionable
ETON Eton Pharmaceuticals	30	25.69 million	22.31 million	Optionable
HBPCF Helix BioPharma	9	229.44 million	212.00 million	Not Optionable
SBBP Strongbridge Biopharma	72	67.83 million	N/A	Optionable

SBBP, ETON, APTX, and HBPCF Headlines

Source	Headline
	Rising Investment in Patient Support Drives a Greater Biopharma Focus on Measurement fiercepharma.com - March 5 at 7:51 AM
	Matinas BioPharma Holdings Inc (MTNB) investing.com - February 10 at 12:33 PM
	Lytix Biopharma As Share Price (LYTIX.OL) lse.co.uk - November 15 at 2:21 AM
	Ambrx Biopharma Inc AMAM morningstar.com - November 4 at 7:36 PM
	Biopharma’s rapid transition to omnichannel marketing pharmaphorum.com - September 11 at 9:18 AM
	HILS Hillstream BioPharma, Inc. seekingalpha.com - August 19 at 3:55 PM
	ABUS - Arbutus Biopharma Corporation finance.yahoo.com - July 1 at 12:38 PM
	The Nominees for Best Biopharma CEO of 2015 Are... thestreet.com - April 25 at 8:23 AM
	Day One Biopharma Shares Rise 13% After Positive Topline Results for Tovorafenib marketwatch.com - January 11 at 9:43 PM
	Biopharma Soars to the Computational Clouds genengnews.com - October 9 at 12:47 PM
	Accord BioPharma Partners with StoryMD to Deliver Advanced Prostate Cancer Educational Content to Clinicians and Patients markets.businessinsider.com - September 22 at 10:04 AM
	Strongbridge Biopharma plc Announces Court Hearing Date to Approve Proposed Acquisition by ... apnews.com - September 23 at 5:49 PM
	Strongbridge Biopharma plc Announces Court Hearing Date to Approve Proposed Acquisition by Xeris Pharmaceuticals, Inc. finance.yahoo.com - September 23 at 5:49 PM
	Press Release: Xeris Pharmaceuticals Stockholders Approve Acquisition of Strongbridge Biopharma sharecast.com - September 14 at 5:56 PM
	Xeris Pharmaceuticals Stockholders Approve Acquisition of Strongbridge Biopharma stockhouse.com - September 14 at 5:56 PM
	Strongbridge Biopharma plc Announces Shareholder Approval of Proposed Acquisition by Xeris ... apnews.com - September 9 at 12:31 PM
	Leading Independent Proxy Advisory Firm ISS Recommends Strongbridge Biopharma plc Shareholders ... apnews.com - August 31 at 7:54 AM
	Second Leading Independent Proxy Advisory Firm Glass Lewis Recommends Strongbridge Biopharma plc Shareholders Vote "FOR" the Transaction With Xeris tmcnet.com - August 31 at 7:54 AM
	Second Leading Independent Proxy Advisory Firm Glass Lewis Recommends Strongbridge Biopharma plc Shareholders Vote “FOR” the Transaction With Xeris finance.yahoo.com - August 31 at 7:54 AM
	Strongbridge Biopharma plc (NASDAQ: SBBP) Have Dropped -20.16% YTD, What Will Happen Next marketingsentinel.com - August 14 at 7:50 AM
	Strongbridge Biopharma: Q2 Earnings Snapshot sfgate.com - August 5 at 8:43 AM
	Strongbridge Biopharma plc Reports Second Quarter 2021 Financial Results and Provides Corporate Update finance.yahoo.com - August 5 at 8:43 AM
	Strongbridge Biopharma plc Announces Commencement of Mailing of Proxy Statement finance.yahoo.com - August 2 at 9:34 AM
	Strongbridge Biopharma plc (NASDAQ:SBBP) Shares Plunges -8.08% In A Week – But Can It Keep Rising? marketingsentinel.com - July 31 at 9:50 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Aptinyx

NASDAQ:APTX

Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. Its lead product candidate NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase I clinical trial to treat opioid use disorder, or OUD; and in preclinical trial for the treatment of alcohol use disorder, or AUD. The company has a research collaboration agreement with Allergan plc. Aptinyx Inc. was incorporated in 2015 and is headquartered in Evanston, Illinois.

Eton Pharmaceuticals

NASDAQ:ETON

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

Helix BioPharma

OTCMKTS:HBPCF

Helix BioPharma Corp. operates as an immune-oncology company in Canada. It is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University Hospital Tuebingen to assess the therapeutic response of L-DOS47 in cancer models expressing CEACAM6, with advanced preclinical metabolic imaging. The company is headquartered in Toronto, Canada.

Strongbridge Biopharma

NASDAQ:SBBP

Strongbridge Biopharma Plc operates as a commercial-stage biopharmaceutical company, which focuses on the development and commercialization of therapies for rare diseases. Its pipeline is comprised of Keveyis, Macrilen, Recorlev, and Veldoreotide. The company was founded in 1996 and is headquartered in Trevose, PA.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial